AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10510139 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol hydrochloride 20 mg once daily (Oriental school children)
Number of subjects: 48
Study 7577283 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 1.5 mg kg‐1 i.v.
Number of subjects: 0
Study 7577283 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 0
Study 1685458 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (100 mg per capsule, 2 capsules once daily for 3 days)
Number of subjects: 50
Study 1685458 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 capsules once daily for 3 days)
Number of subjects: 50
Study 1685458 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 50
Study 1685458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7139566 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (70 mg/m2)
Number of subjects: 200
Study 7139566 — intervention group
Group type: COMPARATOR
Intervention: Vincristine (1.4 mg/m2) and Adriamycin (50 mg/m2)
Number of subjects: 200
Study 7139566 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (750 mg/m2)
Number of subjects: 200
Study 7139566 — intervention group
Group type: COMPARATOR
Intervention: Vincristine-cyclophosphamide-Adriamycin
Number of subjects: 200
Study 7139566 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin alone
Number of subjects: 200
Study 7139566 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin combination
Number of subjects: 200
Study 7139566 — intervention group
Group type: COMPARATOR
Intervention: Vincristine-actinomycin-D-cyclophosphamide
Number of subjects: 200
Study 31421858 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 10
Study 31421858 — intervention group
Group type: COMPARATOR
Intervention: Other treatments (including lithium)
Number of subjects: 10
Study 31421858 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 10
Study 30660594 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for viral suppression at weeks 6, 12, and 24, with amounts increasing from US$4 to $12.5.
Number of subjects: 400
Study 30660594 — intervention group
Group type: COMPARATOR
Intervention: Control group (no financial incentives).
Number of subjects: 400
Study 30660594 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for viral suppression.
Number of subjects: 400
Study 28222546 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Constraint-Induced Movement Therapy (CIMTm) - collective modality
Number of subjects: 36
Study 28222546 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Constraint-Induced Movement Therapy (CIMTm) - individual modality
Number of subjects: 36
Study 27162126 — intervention group
Group type: EXPERIMENTAL
Intervention: MGDRx Eyebag(®)
Number of subjects: 12
Study 27162126 — intervention group
Group type: EXPERIMENTAL
Intervention: EyeDoctor(®)
Number of subjects: 12
Study 27162126 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruder(®)
Number of subjects: 12
Study 27162126 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranquileyes XR™
Number of subjects: 12
Study 27162126 — intervention group
Group type: EXPERIMENTAL
Intervention: Thera°Pearl(®)
Number of subjects: 12
Study 27162126 — intervention group
Group type: COMPARATOR
Intervention: Facecloth warmed with hot tap water
Number of subjects: 12
Study 24457061 — intervention group
Group type: EXPERIMENTAL
Intervention: Postplacental insertion of LNG-IUD
Number of subjects: 42
Study 24457061 — intervention group
Group type: COMPARATOR
Intervention: Delayed insertion of LNG-IUD
Number of subjects: 42
Study 22410289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 × 2 mg
Number of subjects: 24
Study 22410289 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 2 × 160 mg
Number of subjects: 24
Study 22410289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin + Valsartan
Number of subjects: 24
Study 22410289 — intervention group
Group type: COMPARATOR
Intervention: Valsartan monotherapy
Number of subjects: 24
Study 19508973 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC) - three 5 min cycles of right forearm ischaemia with 5 min reperfusion, after anaesthesia.
Number of subjects: 45
Study 19508973 — intervention group
Group type: COMPARATOR
Intervention: Control - deflated cuff placed on the upper arm for 30 min after anaesthesia.
Number of subjects: 45
Study 17239682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of mobilized peripheral blood stem cells (PBSCs) with G-CSF
Number of subjects: 3
Study 17239682 — intervention group
Group type: COMPARATOR
Intervention: G-CSF alone
Number of subjects: 3
Study 17239682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of mobilized PBSCs with G-CSF
Number of subjects: 3
Study 17239682 — intervention group
Group type: COMPARATOR
Intervention: G-CSF administration
Number of subjects: 3
Study 15599747 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g intravenous at induction of anesthesia)
Number of subjects: 1013
Study 15599747 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (1 g intravenous at induction of anesthesia)
Number of subjects: 1013
Study 11954897 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine TDS (0.8, 1.2, and 1.6 mg)
Number of subjects: 445
Study 11954897 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine TDS
Number of subjects: 445
Study 11954897 — intervention group
Group type: COMPARATOR
Intervention: Placebo TDS
Number of subjects: 445
Study 9706921 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking group (mandatory oral fluids, approximately 150 mL)
Number of subjects: 726
Study 9706921 — intervention group
Group type: COMPARATOR
Intervention: Nondrinking group (no oral fluids)
Number of subjects: 726
Study 8561443 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildiem 60 mg (240 mg total daily dose in three divided doses)
Number of subjects: 12
Study 8561443 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-Tildiem 120 mg (two daily doses)
Number of subjects: 12
Study 8561443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30170304 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil (20 g/d for 12 weeks)
Number of subjects: 66
Study 30170304 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (20 g/d for 12 weeks)
Number of subjects: 66
Study 29240854 — intervention group
Group type: EXPERIMENTAL
Intervention: Product containing human fibroblast-derived growth factors
Number of subjects: 0
Study 29240854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25414081 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal instrument placement
Number of subjects: 478
Study 23406052 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan-naproxen (Treximet®)
Number of subjects: 30
Study 23406052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20679180 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg per day for 8 days)
Number of subjects: 0
Study 20679180 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (adenosine receptor antagonist)
Number of subjects: 0
Study 17227688 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoster vaccine potency 58,000 plaque-forming units/dose
Number of subjects: 698
Study 17227688 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoster vaccine potency 207,000 plaque-forming units/dose
Number of subjects: 698
Study 16271341 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with a positive history of constipation in parents
Number of subjects: 2680
Study 16271341 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with anorectal disorders
Number of subjects: 2680
Study 16271341 — intervention group
Group type: EXPERIMENTAL
Intervention: Children aged 1-2 years
Number of subjects: 2680
Study 16271341 — intervention group
Group type: EXPERIMENTAL
Intervention: Children older than 2 years
Number of subjects: 2680
Study 16271341 — intervention group
Group type: EXPERIMENTAL
Intervention: Children living in households with more persons and rooms
Number of subjects: 2680
Study 16271341 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with painful defecation episodes
Number of subjects: 2680
Study 12140349 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (500 mg)
Number of subjects: 47
Study 12140349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 10080053 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (20 mg/kg loading dose)
Number of subjects: 13
Study 10080053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 10080053 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 13
Study 7589767 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 200-300 mg once daily
Number of subjects: 100
Study 7589767 — intervention group
Group type: COMPARATOR
Intervention: Captopril 12.5-25 mg twice daily
Number of subjects: 100
Study 7589767 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem and Captopril
Number of subjects: 100
Study 7589767 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 100
Study 2262955 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting penicillin
Number of subjects: 179
Study 7206848 — intervention group
Group type: EXPERIMENTAL
Intervention: Health screening plus health education
Number of subjects: 165
Study 7206848 — intervention group
Group type: COMPARATOR
Intervention: Health screening control
Number of subjects: 165
Study 7206848 — intervention group
Group type: COMPARATOR
Intervention: No contact comparison
Number of subjects: 165
Study 31562798 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with fluoropolymer‐based cobalt‐chromium everolimus‐eluting stents
Number of subjects: 1905
Study 31562798 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1905
Study 31562798 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1905
Study 28911925 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexibleMIB
Number of subjects: 312
Study 28911925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 28911925 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest
Number of subjects: 312
Study 25843821 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.25 μg/kg/minute (group 1)
Number of subjects: 20
Study 25843821 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.75 μg/kg/minute (group 3)
Number of subjects: 20
Study 25108752 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping with exercise
Number of subjects: 54
Study 25108752 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy with exercise
Number of subjects: 54
Study 22838386 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic bacterium Enterococcus faecium NCIMB 10415
Number of subjects: 0
Study 22838386 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-supplemented)
Number of subjects: 0
Study 19440896 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral skills training program
Number of subjects: 160
Study 19440896 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) control condition
Number of subjects: 160
Study 17439512 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (10 mg rabeprazole + 750 mg amoxicillin + 200 mg clarithromycin twice daily for 7 days)
Number of subjects: 479
Study 17439512 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (10 mg rabeprazole + 750 mg amoxicillin + 400 mg clarithromycin twice daily for 7 days)
Number of subjects: 479
Study 17439512 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (20 mg rabeprazole + 750 mg amoxicillin + 200 mg clarithromycin twice daily for 7 days)
Number of subjects: 479
Study 17439512 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (20 mg rabeprazole + 750 mg amoxicillin + 400 mg clarithromycin twice daily for 7 days)
Number of subjects: 479
Study 17439512 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-susceptible strains
Number of subjects: 479
Study 17439512 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-resistant strains
Number of subjects: 479
Study 17439512 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive metabolizers
Number of subjects: 479
Study 17439512 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor metabolizers
Number of subjects: 479
Study 16312924 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling lateral cervical Jiaji group
Number of subjects: 72
Study 16312924 — intervention group
Group type: COMPARATOR
Intervention: Traditional Jiaji group
Number of subjects: 72
Study 12086370 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 256 microg
Number of subjects: 438
Study 12086370 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 128 microg
Number of subjects: 438
Study 12086370 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 200 microg
Number of subjects: 438
Study 12086370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study 9459252 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine 2% administered through a 25-gauge needle (lido-25)
Number of subjects: 40
Study 9459252 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine 2% mixed with sodium bicarbonate administered through a 25-gauge needle (lido-bicarb-25)
Number of subjects: 40
Study 9459252 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine 2% administered through a 30-gauge needle (lido-30)
Number of subjects: 40
Study 9459252 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine 2% mixed with sodium bicarbonate administered through a 30-gauge needle (lido-bicarb-30)
Number of subjects: 40
Study 9459252 — intervention group
Group type: COMPARATOR
Intervention: lido-bicarb-30
Number of subjects: 40
Study 7887377 — intervention group
Group type: EXPERIMENTAL
Intervention: c7E3 Fab (IIb/IIIa platelet receptor antagonist)
Number of subjects: 2099
Study 7887377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2099
Study 2116119 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-lumen catheters
Number of subjects: 112
Study 2116119 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-lumen catheters
Number of subjects: 112
Study 883331 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment (partial mastectomy plus axillary dissection plus postoperative radiotherapy)
Number of subjects: 302
Study 883331 — intervention group
Group type: COMPARATOR
Intervention: Radical mastectomy
Number of subjects: 302
Study 883331 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional radiotherapy to supraclavicular and internal mammary node areas
Number of subjects: 302
Study 883331 — intervention group
Group type: COMPARATOR
Intervention: No additional radiotherapy
Number of subjects: 302
Study 30653423 — intervention group
Group type: EXPERIMENTAL
Intervention: Site-specific therapy based on gene expression profiling
Number of subjects: 130
Study 30653423 — intervention group
Group type: COMPARATOR
Intervention: Empirical chemotherapy with paclitaxel and carboplatin (PC)
Number of subjects: 130
Study 30653423 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted more-responsive tumor types
Number of subjects: 130
Study 30653423 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted less-responsive tumor types
Number of subjects: 130
Study 30429461 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled recombinant fibroblast growth factor-2 (rFGF-2)
Number of subjects: 6
Study 30429461 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoke exposure
Number of subjects: 6
Study 30429461 — intervention group
Group type: COMPARATOR
Intervention: Elastase-induced emphysema model
Number of subjects: 6
Study 27161105 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 × 300 mg/d WS® 5570
Number of subjects: 0
Study 27161105 — intervention group
Group type: COMPARATOR
Intervention: 20 mg/d paroxetine
Number of subjects: 0
Study 24141008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 242
Study 24141008 — intervention group
Group type: COMPARATOR
Intervention: Control (no UDCA)
Number of subjects: 242
Study 22360152 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 72
Study 22360152 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 72
Study 19410035 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl nitrate (GN) 15 mg/24 hours transdermal patch
Number of subjects: 806
Study 19410035 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) identical-looking patch
Number of subjects: 806
Study 17656180 — intervention group
Group type: EXPERIMENTAL
Intervention: CARRA/LNG gel (0.75 mg levonorgestrel)
Number of subjects: 24
Study 17656180 — intervention group
Group type: COMPARATOR
Intervention: Carraguard (CARRA) gel
Number of subjects: 24
Study 15945342 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapies
Number of subjects: 0
Study 11874925 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein (HP) diet
Number of subjects: 54
Study 11874925 — intervention group
Group type: COMPARATOR
Intervention: Lower-Protein (LP) diet
Number of subjects: 54
Study 10593346 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine and phentermine
Number of subjects: 31
Study 10593346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 7760989 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines (diazepam, lorazepam) and benzodiazepine-like anxiolytics (alpidem, suriclone)
Number of subjects: 0
Study 7760989 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT-3 antagonist (ondansetron)
Number of subjects: 0
Study 7760989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2139523 — intervention group
Group type: EXPERIMENTAL
Intervention: tamoxifen (TAM) (20 mg/die) until progression
Number of subjects: 60
Study 2139523 — intervention group
Group type: COMPARATOR
Intervention: tamoxifen (TAM) (20 mg/die for 14 days) then medroxyprogesterone acetate (MPA) (1500 mg/die p.o. for 14 days)
Number of subjects: 60
Study 6998390 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cephradine
Number of subjects: 0
Study 6998390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cephradine
Number of subjects: 0
Study 6998390 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical and intravenous cephradine
Number of subjects: 0
Study 6998390 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic
Number of subjects: 0
Study 29626134 — intervention group
Group type: EXPERIMENTAL
Intervention: mTICI 2C
Number of subjects: 290
Study 29626134 — intervention group
Group type: EXPERIMENTAL
Intervention: mTICI 3
Number of subjects: 290
Study 29626134 — intervention group
Group type: EXPERIMENTAL
Intervention: mTICI 2C and 3 combined
Number of subjects: 290
Study 29626134 — intervention group
Group type: COMPARATOR
Intervention: mTICI 2B
Number of subjects: 290
Study 26970480 — intervention group
Group type: EXPERIMENTAL
Intervention: VP shunt insertion plus dopamine oral therapy (group A)
Number of subjects: 30
Study 26970480 — intervention group
Group type: COMPARATOR
Intervention: VP shunt alone (group B)
Number of subjects: 30
Study 25483667 — intervention group
Group type: EXPERIMENTAL
Intervention: ID 9 μg intradermal vaccine
Number of subjects: 80
Study 25483667 — intervention group
Group type: COMPARATOR
Intervention: IM 15 μg intramuscular vaccine
Number of subjects: 80
Study 22300528 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (anti-tumor necrosis factor-alpha)
Number of subjects: 234
Study 22300528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 20397759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (n = 37)
Number of subjects: 75
Study 20397759 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 38)
Number of subjects: 75
Study 18701020 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes specific formula (Diason low energy: 313.8 kJ/100 ml)
Number of subjects: 71
Study 18701020 — intervention group
Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 71
Study 15806000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal R112 (3 mg/nostril every 4 hours x 2)
Number of subjects: 319
Study 15806000 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 319
Study 15806000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal R112
Number of subjects: 319
Study 12879672 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 250
Study 12879672 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine
Number of subjects: 250
Study 12879672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 250
Study 12879672 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 250
Study 12879672 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 250
Study 10382126 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin, 500 mg bid for 2 weeks plus RBC, 400 mg bid for 4 weeks
Number of subjects: 383
Study 10382126 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin, 500 mg tid for 2 weeks plus RBC, 400 mg bid for 4 weeks
Number of subjects: 383
Study 8884146 — intervention group
Group type: EXPERIMENTAL
Intervention: Active therapy (600 mg/day of GLA)
Number of subjects: 39
Study 8884146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 2056983 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam plus ketamine
Number of subjects: 129
Study 2056983 — intervention group
Group type: COMPARATOR
Intervention: Midazolam plus placebo
Number of subjects: 129
Study 6362471 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated Conjuvac Timothy tablets
Number of subjects: 12
Study 6362471 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated Whole Timothy pollen tablets
Number of subjects: 12
Study 6362471 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated placebo tablets
Number of subjects: 12